clinical trial · NCT02846987
Study of Abemaciclib in Dedifferentiated Liposarcoma
SarcomaDedifferentiated LiposarcomaAbemaciclib
brief summary
The purpose of this study is to test any good and bad effects of the study drug called Abemaciclib. Abemaciclib could shrink your cancer but it could also cause side effects. Researchers hope to learn if the study drug will delay the growth of the cancer or shrink the cancer by at least one quarter compared to its present size. Abemaciclib is not FDA approved and has not been tested in liposarcoma, but it has shrunk tumors in patients with breast cancer, lymphoma, and lung cancer.
started
Jul 1, 2016
primary completion
Jul 1, 2027
completion
Jul 1, 2027
last updated
Jun 8, 2026
official title
Phase 2 Study of Abemaciclib (LY2835219) in Dedifferentiated Liposarcoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol